Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration as Clinical Endpoints

• Age ≥ 50 years
• Sufficient knowledge of the French language
• Ability to give personal, express, free, and informed consent
• Ability to comply with the requirements of the protocol
• Person covered by Social Security
• Clarity of the ocular environment, adequate pupil dilation to allow the collection of good quality images, as determined by the investigator

Additional inclusion criteria for group 1, healthy subjects:

• No detectable visual pathologies
• Best monocular visual acuity ≥ 8/10

Additional inclusion criteria for group 2, subjects with LMA, early AMD, or intermediate AMD without atrophy:

• Diagnosis of AMD, early AMD, or intermediate AMD
• Absence of geographic atrophy
• Presence of drusen (diameter > 63 µm) with or without pigmentary changes

Additional inclusion criteria for group 3, subjects with dry AMD with perifoveal atrophy:

• Diagnosis of atrophic AMD
• Presence of drusen (diameter > 125 µm)
• Location of geographic atrophy as determined by the investigator: extrafoveal, juxtafoveal
• Preservation of central vision confirmed by the investigator based on a comprehensive and integrated interpretation of SD-OCT, FAF, retinography, and best corrected visual acuity examinations.

Additional inclusion criteria for group 4, Subject with dry AMD with foveal atrophy:

• Diagnosis of atrophic AMD
• Presence of drusen (diameter > 125 µm)
• Investigator's localization of geographic atrophy: retrofoveal
• Central vision impairment confirmed by the investigator based on a comprehensive and integrated interpretation of SD-OCT, FAF, retinography, and best corrected visual acuity examinations.

Exclusion Criteria:

• Pregnant women, women in labor, or breastfeeding women
• Subjects undergoing drug treatments that may cause motor, visual, vestibular, or cognitive disorders (PSA, neuroleptics, etc.) or that could interfere with the study examinations
• Any concomitant intraocular condition in the eye being studied (e.g., glaucoma or cataract)
• Any retinal pathology that could cause retinal atrophy other than AMD (eliminate dystrophy, chronic CRSC, pachyatrophy, resorption of vitelliform material with atrophy, high myopia, etc.)
• Known systemic disease that, in the investigator's opinion, would prevent active participation in the study
• Participation in any other therapeutic study evaluating a drug.
• Subjects with cognitive impairment, illiterate subjects, and subjects who do not speak the national language.
• Persons subject to enhanced protection or legal safeguards (guardianship, trusteeship).